

NR5A2 Promotes Cell Growth and Resistance to Temozolomide Through Regulating Notch Signal Pathway in Glioma [Retraction]

Yang Q, Deng L, Li J, Miao P, Liu W, Huang Q. *Onco Targets Ther.* 2020;13:10231–10244. <https://doi.org/10.2147/OTT.S243833>

We, the Editors and Publisher of the journal *OncoTargets and Therapy*, have retracted the published article.

After publication, concerns have been raised by a third party in 2023 about the integrity of the data in Figures 1 and 6 of the article.

Further investigation conducted by the Journal and Publisher confirmed the following:

- Unusual similarities between the immunohistochemistry staining images in Figures 1C and 6D which are representative of different treatment conditions.
- Unexpected similarities within the Western blots shown in Figure 3C.
- Unexpected similarities between the Western blots in Figure 2B and the Western blot data in the following previously published article from an unrelated author group:

Luo F, Zhou Z, Cai J, Du W. DUB3 Facilitates Growth and Inhibits Apoptosis Through Enhancing Expression of EZH2 in Oral Squamous Cell Carcinoma. *Onco Targets Ther.* 2020;13:1447–1460. <https://doi.org/10.2147/OTT.S230577>

When approached for an explanation, the authors did not respond to the queries raised by the Journal and Publisher.

As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The corresponding author listed in this publication has been informed.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>

Dovepress
Taylor & Francis Group

<https://doi.org/10.2147/OTT.S633639>

<https://doi.org/10.2147/OTT.S633639>
Received: 17 June 2026
Accepted: 17 June 2026
Published: 19 June 2026

OncoTargets and Therapy 2026;19 633639



© 2026 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (<http://creativecommons.org/licenses/by-nc/4.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).